Searching for the gatekeeper oncogene of prostate cancer

Critical Reviews in Oncology/Hematology

Volumn 46, Issue SUPPL., 2003, Pages 11-20

  Gelmann, Edward P ^a  

^a GEORGETOWN UNIVERSITY   (United States)

Author keywords

HPC1; HPC2; HPCX; NKX3.1; Oncogene; Prostate cancer; PTEN

Indexed keywords

ANDROGEN; PROTEIN; PROTEIN ELAC; PROTEIN GAP; PROTEIN HPC1; PROTEIN HPC2; PROTEIN HPCX; PROTEIN PCAP; RAS ASSOCIATION DOMAIN FAMILY PROTEIN 1A; TRANSCRIPTION FACTOR EGR 1; UNCLASSIFIED DRUG;

BIOCHEMISTRY; CANCER FAMILY; CANCER RISK; CARCINOGENESIS; CONFERENCE PAPER; CYTOGENETICS; DNA MICROARRAY; EXPERIMENTAL MODEL; FAMILY HISTORY; GENE EXPRESSION; GENE FUNCTION; GENE LOCUS; GENE MUTATION; GENE TARGETING; GENETIC ANALYSIS; GENETIC ENGINEERING; HEREDITY; HETEROZYGOSITY LOSS; HIGH RISK POPULATION; HORMONE DEPENDENCE; HUMAN; KARYOTYPE; MOLECULAR BIOLOGY; NONHUMAN; ONCOGENE; PATHOGENESIS; PROSTATE ADENOCARCINOMA; PROSTATE CARCINOMA; PROSTATE EPITHELIUM; PROTEIN FAMILY; SUPPRESSOR GENE; TUMOR PROMOTION;

EID: 0038354577     PISSN: 10408428     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1040-8428(03)00060-X     Document Type: Conference Paper

References (127)

1. Kinzler K.W., Vogelstein B. Lessons from hereditary colorectal cancer. Cell. 87:1996;159-170.
2. Druker B.J., Talpaz M., Resta D.J., et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New Engl. J. Med. 344:2001;1031-1037.
3. Druker B.J., Sawyers C.L., Kantarjian H., et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. New Engl. J. Med. 344:2001;1038-1042.
4. Apperley J.F., Gardembas M., Melo J.V., et al. Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta. New Engl. J. Med. 347:2002;481-487.
5. Demetri G.D., von Mehren M., Blanke C.D., et al. Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. New Engl. J. Med. 347:2002;472-480.
6. Fearon E.R., Vogelstein B. A genetic model for colorectal tumorigenesis. Cell. 61:1990;759-767.
7. Morin P.J. Beta-catenin signaling and cancer. Bioessays. 21:1999;1021-1030.
8. Morin P.J., Sparks A.B., Korinek V., et al. Activation of beta-catenin-Tcf signaling in colon cancer by mutations in beta-catenin or APC. Science. 275:1997;1787-1790.
9. Bodmer W.F., Bailey C.J., Bodmer J., et al. Localization of the gene for familial adenomatous polyposis on chromosome 5. Nature. 328:1987;614-616.
10. Powell S.M., Zilz N., Beazer-Barclay Y., et al. APC mutations occur early during colorectal tumorigenesis. Nature. 359:1992;235-237.
11. Nakamura Y., Nishisho I., Kinzler K.W., et al. Mutations of the APC (adenomatous polyposis coli) gene in FAP (familial polyposis coli) patients and in sporadic colorectal tumors. Tohoku J. Exp. Med. 168:1992;141-147.
12. Linehan W.M., Lerman M.I., Zbar B. Identification of the von Hippel-Lindau (VHL) gene. Its role in renal cancer. J. Am. Med. Assoc. 273:1995;564-570.
13. Cleutjens K.B., van Eekelen C.C., van der Korput H.A., Brinkmann A.O., Trapman J. Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter. J. Biol. Chem. 271:1996;6379-6388.
14. Massenkeil G., Oberhuber H., Hailemariam S., et al. P53 mutations and loss of heterozygosity on chromosomes 8p, 16q, 17p, and 18q are confined to advanced prostate cancer. Anticancer Res. 14:1994;2785-2790.
15. Lundgren R., Kristoffersson U., Heim S., Mandahl N., Mitelman F. Multiple structural chromosome rearrangements, including del(7q) and del(10q), in an adenocarcinoma of the prostate. Cancer Genet. Cytogenet. 35:1988;103-108.
16. Phillips S.M., Morton D.G., Lee S.J., Wallace D.M., Neoptolemos J.P. Loss of heterozygosity of the retinoblastoma and adenomatous polyposis susceptibility gene loci and in chromosomes 10p, 10q and 16q in human prostate cancer. Br. J. Urol. 73:1994;390-395.
17. Konig J.J., Teubel W., Romijn J.C., Schroder F.H., Hagemeijer A. Gain and loss of chromosomes 1, 7, 8, 10, 18, and Y in 46 prostate cancers. Hum. Pathol. 27:1996;720-727.
18. Crundwell M.C., Chughtai S., Knowles M., et al. Allelic loss on chromosomes 8p, 22q and 18q (DCC) in human prostate cancer. Int. J. Cancer. 69:1996;295-300.
19. Carter B.S., Ewing C.M., Ward W.S., et al. Allelic loss of chromosomes 16q and 10q in human prostate cancer. Proc. Natl. Acad. Sci. USA. 87:1990;8751-8755.
20. Smith J.R., Freije D., Carpten J.D., et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 274:1996;1371-1374.
21. Xu J., Zheng S.L., Carpten J.D., et al. Evaluation of linkage and association of HPC2/ELAC2 in patients with familial or sporadic prostate cancer. Am. J. Hum. Genet. 68:2001;901-911.
22. Xu J., Meyers D., Freije D., et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat. Genet. 20:1998;175-179.
23. Tavtigian S.V., Simard J., Teng D.H., et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat. Genet. 27:2001;172-180.
24. Xu J., Zheng S.L., Chang B., et al. Linkage of prostate cancer susceptibility loci to chromosome 1. Hum. Genet. 108:2001;335-345.
25. Neuhausen S.L., Farnham J.M., Kort E., Tavtigian S.V., Skolnick M.H., Cannon-Albright L.A. Prostate cancer susceptibility locus HPC1 in Utah high-risk pedigrees. Hum. Mol. Genet. 8:1999;2437-2442.
26. Ahman A.K., Jonsson B.A., Damber J.E., Bergh A., Emanuelsson M., Gronberg H. Low frequency of allelic imbalance at the prostate cancer susceptibility loci HPC1 and 1p36 in Swedish men with hereditary prostate cancer. Genes Chromosomes Cancer. 29:2000;292-296.
27. Berry R., Schaid D.J., Smith J.R., et al. Linkage analyses at the chromosome 1 loci 1q24-25 (HPC1), 1q42.2-43 (PCAP), and 1p36 (CAPB) in families with hereditary prostate cancer. Am. J. Hum. Genet. 66:2000;539-546.
28. Latil A., Cussenot O., Fournier G., Lidereau R. Infrequent allelic imbalance at the major susceptibility HPC1 locus in sporadic prostate tumours. Int. J. Cancer. 71:1997;1118.
29. Gronberg H., Smith J., Emanuelsson M., et al. In Swedish families with hereditary prostate cancer, linkage to the HPC1 locus on chromosome 1q24-25 is restricted to families with early-onset prostate cancer. Am. J. Hum. Genet. 65:1999;134-140.
30. Gronberg H., Isaacs S.D., Smith J.R., et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. J. Am. Med. Assoc. 278:1997;1251-1255.
31. Bergthorsson J.T., Johannesdottir G., Arason A., et al. Analysis of HPC1, HPCX, and PCaP in Icelandic hereditary prostate cancer. Hum. Genet. 107:2000;372-375.
32. Gronberg H., Xu J., Smith J.R., et al. Early age at diagnosis in families providing evidence of linkage to the hereditary prostate cancer locus (HPC1) on chromosome 1. Cancer Res. 57:1997;4707-4709.
33. Carpten J., Nupponen N., Isaacs S., et al. Germline mutations in the ribonuclease L gene in families showing linkage with HPC1. Nat. Genet. 30:2002;181-184.
34. Rokman A., Ikonen T., Seppala E.H., et al. Germline alterations of the RNASEL gene, a candidate HPC1 gene at 1q25, in patients and families with prostate cancer. Am. J. Hum. Genet. 70:2002;1299-1304.
35. Shou J., Soriano R., Hayward S.W., Cunha G.R., Williams P.M., Gao W.Q. Expression profiling of a human cell line model of prostatic cancer reveals a direct involvement of interferon signaling in prostate tumor progression. Proc. Natl. Acad. Sci. USA. 99:2002;2830-2835.
36. Zhou A., Paranjape J., Brown T.L., et al. Interferon action and apoptosis are defective in mice devoid of 2′,5′-oligoadenylate-dependent RNase L. EMBO J. 16:1997;6355-6363.
37. Berthon P., Valeri A., Cohen-Akenine A., et al. Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43. Am. J. Hum. Genet. 62:1998;1416-1424.
38. Gibbs M., Chakrabarti L., Stanford J.L., et al. Analysis of chromosome 1q42.2-43 in 152 families with high risk of prostate cancer. Am. J. Hum. Genet. 64:1999;1087-1095.
39. Maier C., Rosch K., Herkommer K., et al. A candidate gene approach within the susceptibility region PCaP on 1q42.2-43 excludes deleterious mutations of the PCTA-1 gene to be responsible for hereditary prostate cancer. Eur. Urol. 42:2002;301.
40. Lange E.M., Chen H., Brierley K., et al. Linkage analysis of 153 prostate cancer families over a 30-cM region containing the putative susceptibility locus HPCX. Clin. Cancer Res. 5:1999;4013-4020.
41. Stephan D.A., Howell G.R., Teslovich T.M., et al. Physical and transcript map of the hereditary prostate cancer region at xq27. Genomics. 79:2002;41-50.
42. Wang L., McDonnell S.K., Elkins D.A., et al. Role of HPC2/ELAC2 in hereditary prostate cancer. Cancer Res. 61:2001;6494-6499.
43. Meitz J.C., Edwards S.M., Easton D.F., et al. HPC2/ELAC2 polymorphisms and prostate cancer risk: analysis by age of onset of disease. Br. J. Cancer. 87:2002;905-908.
44. Rokman A., Ikonen T., Mononen N., et al. ELAC2/HPC2 involvement in hereditary and sporadic prostate cancer. Cancer Res. 61:2001;6038-6041.
45. Rebbeck T.R., Walker A.H., Zeigler-Johnson C., et al. Association of HPC2/ELAC2 genotypes and prostate cancer. Am. J. Hum. Genet. 67:2000;1014-1019.
46. MacGrogen D., Levy A., Bostwick D., Wagner M., Wells D., Bookstein R. Loss of chromosome arm 8p loci in prostate cancer: mapping by quantitative allelic imbalance. Genes Chromosomes Cancer. 10:1994;151-159.
47. Suzuki H., Emi M., Komiya A., et al. Localization of a tumor suppressor gene associated with progression of human prostate cancer within a 1.2 Mb region of 8p22-p21.3. Genes Chromosomes Cancer. 13:1995;168-174.
48. Kagan J., Stein J., Babaian R.J., et al. Homozygous deletions at 8p22 and 8p21 in prostate cancer implicate these regions as the sites for candidate tumor suppressor genes. Oncogene. 11:1995;2121-2126.
49. Bova G.S., Carter B.S., Bussemakers J.G., et al. Homozygous deletion and frequent allelic loss of chromosome 8p22 loci in human prostate cancer. Cancer Res. 53:1993;3869-3873.
50. Prasad M.A., Trybus T.M., Wojno K.J., Macoska J.A. Homozygous and frequent deletion of proximal 8p sequences in human prostate cancers: identification of a potential tumor suppressor gene site. Genes Chromosomes Cancer. 23:1998;255-262.
51. Macoska J.A., Trybus T.M., Sakr W.A., et al. Fluorescence in situ hybridization analysis of 8p allelic loss and chromosome 8 instability in human prostate cancer. Cancer Res. 54:1994;3824-3830.
52. Macoska J.A., Trybus T.M., Benson P.D., et al. Evidence for three tumor suppressor gene loci on chromosome 8p in human prostate cancer. Cancer Res. 55:1995;5390-5395.
53. Emmert-Buck M.R., Vocke C.D., Pozzatti R.O., et al. Allelic loss on chromosome 8p12-21 in microdissected prostate intraepithelial neoplasia. Cancer Res. 55:1995;2959-2962.
54. Haggman M.J., Wojno K.J., Pearsall C.P., Macoska J.A. Allelic loss of 8p sequences in prostatic intraepithelial neoplasia and carcinoma. Urology. 50:1997;643-647.
55. Vocke C.D., Pozzatti R.O., Bostwick D.G., et al. Analysis of 99 microdissected prostate carcinomas reveals a high frequency of allelic loss on chromosome 8p21-22. Cancer Res. 56:1996;2411-2416.
56. Swalwell J.I., Vocke C.D., Yang Y., et al. Determination of a minimal deletion interval on chromosome band 8p21 in sporadic prostate cancer. Genes Chromosomes Cancer. 33:2002;201-205.
57. Voeller H.J., Augustus M., Madlike V., Bova G.S., Carter K.C., Gelmann E.P. Coding region of NKX3.1, prostate-specific homeobox gene on 8p21, is not mutated in human prostate cancers. Cancer Res. 57:1997;4455-4459.
58. Ornstein D.K., Cinquanta M., Weiler S., et al. Expression studies and mutational analysis of the androgen regulated homeobox gene nkx3.1 in benign and malignant prostate epithelium. J. Urol. 165:2001;1329-1334.
59. Bhatia-Gaur R., Donjacour A.A., Sciavolino P.J., et al. Roles for Nkx3.1 in prostate development and cancer. Genes Dev. 13:1999;966-977.
60. He W.W., Sciavolino P.J., Wing J., et al. A novel human prostate-specific, androgen-regulated homeobox gene (NKX3.1) that maps to 8p21, a region frequently deleted in prostate cancer. Genomics. 43:1997;69-77.
61. Bowen C., Bubendorf L., Voeller H.J., et al. Loss of NKX3.1 expression in human prostate cancers correlates with tumor progression. Cancer Res. 60:2000;6111-6115.
62. Xu L.L., Srikantan V., Sesterhenn I.A., et al. Expression profile of an androgen regulated prostate specific homeobox gene NKX3.1 in primary prostate cancer. J. Urol. 163:2000;972-979.
63. Bieberich C.J., Fujita K., He W.W., Jay G. Prostate-specific and androgen-dependent expression of a novel homeobox gene. J. Biol. Chem. 271:1996;31779-31782.
64. Kos L., Chiang C., Mahon K.A. Mediolateral patterning of somites: multiple axial signals, including Sonic hedgehog, regulate Nkx-3.1 expression. Mech. Dev. 70:1998;25-34.
65. Schneider A., Brand T., Zweigerdt R., Arnold H. Targeted disruption of the nkx3.1 gene in mice results in morphogenetic defects of minor salivary glands: parallels to glandular duct morphogenesis in prostate. Mech. Dev. 95:2000;163-174.
66. Kim M.J., Bhatia-Gaur R., Banach-Petrosky W.A., et al. Nkx3.1 mutant mice recapitulate early stages of prostate carcinogenesis. Cancer Res. 62:2002;2999-3004.
67. Abdulkadir S.A., Magee J.A., Peters T.J., et al. Conditional loss of Nkx3.1 in adult mice induces prostatic intraepithelial neoplasia. Mol. Cell. Biol. 22:2002;1495-1503.
68. Kim M.J., Cardiff R.D., Desai N., et al. Cooperativity of Nkx3.1 and Pten loss of function in a mouse model of prostate carcinogenesis. Proc. Natl. Acad. Sci. USA. 99:2002;2884-2889.
69. Steadman D.J., Giuffrida D., Gelmann E.P. DNA-binding sequence of the human prostate-specific homeodomain protein NKX3.1. Nucleic Acids Res. 28:2000;2389-2395.
70. Carson J.A., Fillmore R.A., Schwartz R.J., Zimmer W.E. The smooth muscle gamma-actin gene promoter is a molecular target for the mouse bagpipe homologue, mNkx3-1, and serum response factor. J. Biol. Chem. 275:2000;39061-39072.
71. Gruschus J.M., Tsao D.H., Wang L.H., Nirenberg M., Ferretti J.A. Interactions of the vnd/NK-2 homeodomain with DNA by nuclear magnetic resonance spectroscopy: basis of binding specificity. Biochemistry. 36:1997;5372-5380.
72. Harvey R.P. NK-2 homeobox genes and heart development. Dev. Biol. 178:1996;203-216.
73. Qian Y.Q., Furukubo-Tokunaga K., Resendez-Perez D., Muller M., Gehring W.J., Wuthrich K. Nuclear magnetic resonance solution structure of the fushi tarazu homeodomain from Drosophila and comparison with the Antennapedia homeodomain. J. Mol. Biol. 238:1994;333-345.
74. Gelmann E.P., Steadman D.J., Ma J., et al. Occurrence of NKX3.1 C154T polymorphism in men with and without prostate cancer and studies of its effect on protein function. Cancer Res. 62:2002;2654-2659.
75. Chen C.Y., Schwartz R.J. Recruitment of the tinman homolog Nkx-2.5 by serum response factor activates cardiac alpha-actin gene transcription. Mol. Cell. Biol. 16:1996;6372-6384.
76. Sepulveda J.L., Belaguli N., Nigam V., Chen C.Y., Nemer M., Schwartz R.J. GATA-4 and Nkx-2.5 coactivate Nkx-2 DNA binding targets: role for regulating early cardiac gene expression. Mol. Cell. Biol. 18:1998;3405-3415.
77. Chen H., Nandi A.K., Li X., Bieberich C.J. NKX-3.1 interacts with prostate-derived Ets factor and regulates the activity of the PSA promoter. Cancer Res. 62:2002;338-340.
78. Voeller H.J., Orford K.W., Sugars L.Y., Vickers C., Gelmann E.P. Analysis of oncogenes and loss of heterozygosity on chromosome 10q22-qter in prostatic adenocarcinoma. Proc. Am. Assoc. Cancer Res. 35:1994;574-574.
79. Colombo B.M., Roz L., Broggi G., Finocchiaro G. Progress in the definition of the region of loss of heterozygosity of chromosome 10q in glioblastomas. Proc. Am. Assoc. Cancer Res. 35:1994;574. AB 3422.
80. Steck P.A., Pershouse M.A., Jasser S.A., et al. Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers. Nat. Genet. 15:1997;356-362.
81. Feilotter H.E., Nagai M.A., Boag A.H., Eng C., Mulligan L.M. Analysis of PTEN and the 10q23 region in primary prostate carcinomas. Oncogene. 16:1998;1743-1748.
82. Li J., Yen C., Liaw D., et al. PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer. Science. 275:1997;1943-1947.
83. Maehama T., Dixon J.E. PTEN: a tumour suppressor that functions as a phospholipid phosphatase. Trends Cell Biol. 9:1999;125-128.
84. Stambolic V., Suzuki A., de la Pompa J.L., et al. Negative regulation of PKB/Akt-dependent cell survival by the tumor suppressor PTEN. Cell. 95:1998;29-39.
85. Sun H., Lesche R., Li D.M., et al. PTEN modulates cell cycle progression and cell survival by regulating phosphatidylinositol 3,4,5,-trisphosphate and Akt/protein kinase B signaling pathway. Proc. Natl. Acad. Sci. USA. 96:1999;6199-6204.
86. Wu X., Senechal K., Neshat M.S., Whang Y.E., Sawyers C.L. The PTEN/MMAC1 tumor suppressor phosphatase functions as a negative regulator of the phosphoinositide 3-kinase/Akt pathway. Proc. Natl. Acad. Sci. USA. 95:1998;15587-15591.
87. Myers M.P., Pass I., Batty I.H., et al. The lipid phosphatase activity of PTEN is critical for its tumor suppressor function. Proc. Natl. Acad. Sci. USA. 95:1998;13513-13518.
88. Cantley L.C., Neel B.G. New insights into tumor suppression: PTEN suppresses tumor formation by restraining the phosphoinositide 3-kinase/AKT pathway. Proc. Natl. Acad. Sci. USA. 96:1999;4240-4245.
89. Datta S.R., Dudek H., Tao X., et al. Akt phosphorylation of BAD couples survival signals to the cell-intrinsic death machinery. Cell. 91:1997;231-241.
90. Liang J., Zubovitz J., Petrocelli T., et al. PKB/Akt phosphorylates p27, impairs nuclear import of p27 and opposes p27-mediated G1 arrest. Nat. Med. 8:2002;1153-1160.
91. Kip1 at threonine 157 and modulation of its cellular localization. Nat. Med. 8:2002;1145-1152.
92. Viglietto G., Motti M.L., Bruni P., et al. Cytoplasmic relocalization and inhibition of the cyclin-dependent kinase inhibitor p27Kip1 by PKB/Akt-mediated phosphorylation in breast cancer. Nat. Med. 8:2002;1136-1144.
93. Gray I.C., Stewart L.M., Phillips S.M., et al. Mutation and expression analysis of the putative prostate tumour-suppressor gene PTEN. Br. J. Cancer. 78:1998;1296-1300.
94. Pesche S., Latil A., Muzeau F., et al. PTEN/MMAC1/TEP1 involvement in primary prostate cancers. Oncogene. 16:1998;2879-2883.
95. McMenamin M.E., Soung P., Perera S., Kaplan I., Loda M., Sellers W.R. Loss of PTEN expression in paraffin-embedded primary prostate cancer correlates with high Gleason score and advanced stage. Cancer Res. 59:1999;4291-4296.
96. Whang Y.E., Wu X., Suzuki H., et al. Inactivation of the tumor suppressor PTEN/MMAC1 in advanced human prostate cancer through loss of expression. Proc. Natl. Acad. Sci. USA. 95:1998;5246-5250.
97. Suzuki H., Freije D., Nusskern D.R., et al. Interfocal heterogeneity of PTEN/MMAC1 gene alterations in multiple metastatic prostate cancer tissues. Cancer Res. 58:1998;204-209.
98. Cairns P., Okami K., Halachmi S., et al. Frequent inactivation of PTEN/MMAC1 in primary prostate cancer. Cancer Res. 57:1997;4997-5000.
99. Dong J.T., Sipe T.W., Hyytinen E.R., et al. PTEN/MMAC1 is infrequently mutated in pT2 and pT3 carcinomas of the prostate. Oncogene. 17:1998;1979-1982.
100. Wang S.I., Parsons R., Ittmann M. Homozygous deletion of the PTEN tumor suppressor gene in a subset of prostate adenocarcinomas. Clin. Cancer Res. 4:1998;811-815.
101. Dong J.T., Li C.L., Sipe T.W., Frierson H.F. Jr. Mutations of PTEN/MMAC1 in primary prostate cancers from Chinese patients. Clin. Cancer Res. 7:2001;304-308.
102. Orikasa K., Fukushige S., Hoshi S., et al. Infrequent genetic alterations of the PTEN gene in Japanese patients with sporadic prostate cancer. J. Hum. Genet. 43:1998;228-230.
103. Suzuki A., de la Pompa J.L., Stambolic V., et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8:1998;1169-1178.
104. Di Cristofano A., Pesce B., Cordon-Cardo C., Pandolfi P.P. Pten is essential for embryonic development and tumour suppression. Nat. Genet. 19:1998;348-355.
105. Podsypanina K., Ellenson L.H., Nemes A., et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl. Acad. Sci. USA. 96:1999;1563-1568.
106. Kwabi-Addo B., Giri D., Schmidt K., et al. Haploinsufficiency of the Pten tumor suppressor gene promotes prostate cancer progression. Proc. Natl. Acad. Sci. USA. 98:2001;11563-11568.
107. Di Cristofano A., De Acetis M., Koff A., Cordon-Cardo C., Pandolfi P.P. Pten and p27KIP1 cooperate in prostate cancer tumor suppression in the mouse. Nat. Genet. 27:2001;222-224.
108. Koul D., Shen R., Garyali A., Ke L.D., Liu T.J., Yung W.K. MMAC/PTEN tumor suppressor gene regulates vascular endothelial growth factor-mediated angiogenesis in prostate cancer. Int. J. Oncol. 21:2002;469-475.
109. Giri D., Ittmann M. Inactivation of the PTEN tumor suppressor gene is associated with increased angiogenesis in clinically localized prostate carcinoma. Hum. Pathol. 30:1999;419-424.
110. Sharma M., Chuang W.W., Sun Z. Phosphatidylinositol 3-kinase/Akt stimulates androgen pathway through GSK3beta inhibition and nuclear beta-catenin accumulation. J. Biol. Chem. 277:2002;30935-30941.
111. Gelmann E.P. Molecular biology of the androgen receptor. J. Clin. Oncol. 20:2002;3001-3015.
112. Cooney K.A., Tsou H.C., Petty E.M., et al. Absence of PTEN germ-line mutations in men with a potential inherited predisposition to prostate cancer. Clin. Cancer Res. 5:1999;1387-1391.
113. Forrest M.S., Edwards S.M., Hamoudi R.A., et al. No evidence of germline PTEN mutations in familial prostate cancer. J. Med. Genet. 37:2000;210-212.
114. Pei L., Peng Y., Yang Y., et al. PRC17, a novel oncogene encoding a Rab GTPase-activating protein, is amplified in prostate cancer. Cancer Res. 62:2002;5420-5424.
115. Rauscher F.J. III, Morris J.F., Tournay O.E., Cook D.M., Curran T. Binding of the Wilms' tumor locus zinc finger protein to the EGR-1 consensus sequence. Science. 250:1990;1259-1262.
116. Hosono S., Gross I., English M.A., Hajra K.M., Fearon E.R., Licht J.D. E-cadherin is a WT1 target gene. J. Biol. Chem. 275:2000;10943-10953.
117. Shimamura R., Fraizer G.C., Trapman J., Lau Y., Saunders G.F. The Wilms' tumor gene WT1 can regulate genes involved in sex determination and differentiation: SRY, Mullerian-inhibiting substance, and the androgen receptor. Clin. Cancer Res. 3:1997;2571-2580.
118. Hamilton T.B., Borel F., Romaniuk P.J. Comparison of the DNA binding characteristics of the related zinc finger proteins WT1 and EGR1. Biochemistry. 37:1998;2051-2058.
119. Jamieson G.A. Jr, Mayforth R.D., Villereal M.L., Sukhatme V.P. Multiple intracellular pathways induce expression of a zinc-finger encoding gene (EGR1): relationship to activation of the Na/H exchanger. J. Cell. Physiol. 139:1989;262-268.
120. Svaren J., Ehrig T., Abdulkadir S.A., Ehrengruber M.U., Watson M.A., Milbrandt J. EGR1 target genes in prostate carcinoma cells identified by microarray analysis. J. Biol. Chem. 275:2000;38524-38531.
121. Adamson E.D., Mercola D. Egr1 transcription factor: multiple roles in prostate tumor cell growth and survival. Tumour Biol. 23:2002;93-102.
122. Abdulkadir S.A., Qu Z., Garabedian E., et al. Impaired prostate tumorigenesis in Egr1-deficient mice. Nat. Med. 7:2001;101-107.
123. Abdulkadir S.A., Carbone J.M., Naughton C.K., Humphrey P.A., Catalona W.J., Milbrandt J. Frequent and early loss of the EGR1 corepressor NAB2 in human prostate carcinoma. Hum. Pathol. 32:2001;935-939.
124. Carter B.S., Epstein J.I., Isaacs W.B. ras Gene mutations in human prostate cancer. Cancer Res. 50:1990;6830-6832.
125. Vos M.D., Ellis C.A., Bell A., Birrer M.J., Clark G.J. Ras uses the novel tumor suppressor RASSF1 as an effector to mediate apoptosis. J. Biol. Chem. 275:2000;35669-35672.
126. Kuzmin I., Gillespie J.W., Protopopov A., et al. The RASSF1A tumor suppressor gene is inactivated in prostate tumors and suppresses growth of prostate carcinoma cells. Cancer Res. 62:2002;3498-3502.
127. Liu L., Yoon J.H., Dammann R., Pfeifer G.P. Frequent hypermethylation of the RASSF1A gene in prostate cancer. Oncogene. 21:2002;6835-6840.